Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Detailed Status

Completed4

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

completed480%

active_not_recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

completedphase_2

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

NCT06437223

active_not_recruitingphase_2

Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

NCT00534560

Clinical Trials (5)

Showing 5 of 5 trials

NCT06437223Phase 2

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

Completed

NCT05727891Phase 2

Evaluation of Tonabersat for DME

Active Not Recruiting

NCT00311662Phase 2

Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

Completed

NCT00332007Phase 2

Tonabersat in the Prophylaxis of Migraine With Aura

Completed

NCT00534560Phase 2

Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5